secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079152
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share
--------------------------------------------------------------------------------

- Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.
- GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).
- Non-GAAP net income $5.2M ($0.16 per share) in Q4; full-year non-GAAP income $13.2M ($0.42 per share).
- Cash, equivalents, restricted cash, and marketable securities totaled $705.5M at year-end, plus $106.3M anticipated tax refund.
- Adjusted EBITDA loss of $4.5M in Q4 and $9.4M for full year 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526079152/0001193125-26-079152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000119312526079152/flgt-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer